Intrathecal injection of tigecycline in treatment of multidrug-resistant meningitis: a case report.

Journal: European journal of hospital pharmacy : science and practice
Published Date:

Abstract

The ubiquitous is an important and troublesome pathogen of nosocomial infection. Multidrug-resistant meningitis is very difficult to treat, usually with high mortality. The disease is generally associated with craniotomy, but rarely with lumbar puncture. However, in our case, a 45-year-old male construction worker suffered multidrug-resistant meningitis associated with lumbar puncture. The patient responded poorly to the initial treatment with an intravenous infusion of tigecycline. However, later treatment with an intrathecal injection of tigecycline (concentration 1 mg/mL) at a dose of 10 mg every 12 hours proved to be highly efficacious. Thus, intrathecal injection of tigecycline should be seriously considered as a treatment for multidrug-resistant meningitis.

Authors

  • Lijiang Wang
    Department of Neurosurgery, Shengli Oilfield Central Hospital of Binzhou Medical University, Dongying, Shandong, China.
  • Jirong Zhang
    Department of Neurosurgery, Shengli Oilfield Central Hospital of Binzhou Medical University, Dongying, Shandong, China.
  • Xiaoqing Yu
    Department of Neurosurgery, Shengli Oilfield Central Hospital of Binzhou Medical University, Dongying, Shandong, China.
  • Jiuzhong Wang
    Department of Neurosurgery, Shengli Oilfield Central Hospital of Binzhou Medical University, Dongying, Shandong, China.
  • Lifeng Cheng
    Department of Neurosurgery, Shengli Oilfield Central Hospital of Binzhou Medical University, Dongying, Shandong, China.
  • Shuzhen Hu
    Department of Neurosurgery, Shengli Oilfield Central Hospital of Binzhou Medical University, Dongying, Shandong, China.
  • Guangliang Han
    Department of Neurosurgery, Shengli Oilfield Central Hospital of Binzhou Medical University, Dongying, Shandong, China.

Keywords

No keywords available for this article.